The first GMP biomimicking “Ex vivo lymphoid niche” cell culture process
Through its patented and proprietary “Ex vivo lymphoid niche” technology, Smart Immune develops a T-cell progenitor-based cell therapy platform, so called ProTcell™ platform. It has been designed to ensure a rapid, complete, and long-lasting immune recovery to fight malignancies and infections.
Those lymphoid progenitors have a remarkable dual potential of differentiation:
- To the T lineage: when directly infused to patients, they complete their differentiation into the thymus recipient to become polyclonal and fully efficient T cells.
-To the NK lineage: when further cultured ex vivo through a dedicated process they can differentiate in early NK effectors.